On Friday, Shares of Intel Corporation (NASDAQ:INTC), gained 0.83% to $29.17.
Intel Security, declared its second phase of advancements to the Intel Security Partner Program to improve profitability and efficiency for distributors and resellers. The first phase of the rollout was declared in October 2014 to create a flexible framework for future enhancements to the program, as distributors and resellers evolve their business models and adapt to the changing customer landscape.
The second phase of the Intel Security Partner Program initiative seeks to innovate and invest in driving differentiation and profitability. Improvements initiated with the second phase comprise:
- Removal of Tiered Pricing: Eliminating tiered pricing allows Intel Security to reallocate funds to more profitable offerings that improve retained margin.
- Improved Deal Registration: Rewards members based upon their Intel Security Partner Program level, by limiting deal registration to one partner per each approved partner-found sales opportunity. This also simplifies the Deal Registration process by consolidating to one registration form.
- New Teaming Plan: Investment in resellers that have committed to building an Intel Security practice and are engaged in adding value to Intel Security found deals. The plan is intended to enhance profitability and deal protection for the partner, streamlining the approval process.
- Improved Incumbency Advantage: Provides additional incentives based on the program level by increasing the discount for resellers as the partner level rises, and automatically rewarding resellers for renewals.
- Partner Level Name Changes: New Platinum, Gold and Silver partnership levels reflect industry standard terms for classifying tiered offerings.
Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.
Shares of AbbVie Inc. (NYSE:ABBV), inclined 1.85% to $68.72, during its last trading session.
AbbVie, declared the European Commission (EC) granted marketing authorization for IMBRUVICA® (ibrutinib) as the first treatment option accessible in all 28 member states of the European Union (EU) for the treatment of Waldenstrom’s macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one preceding therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Pharmacyclics LLC, an AbbVie company, received FDA approval for IMBRUVICA, which is also the first and only FDA-approved treatment for WM in the United States, in January 2015.1 The approval of IMBRUVICA to treat patients with WM triggers a $20 million milestone payment from Janssen.
IMBRUVICA is jointly developed and commercialized in the United States by Pharmacyclics and Janssen Biotech, Inc. In Europe, Janssen-Cilag International NV (Janssen) holds the marketing authorization and its associates market IMBRUVICA in EMEA (Europe, Middle East, Africa), in addition to the rest of the world. IMBRUVICA is already approved in Europe to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) and adult patients with chronic lymphocytic leukemia (CLL) who have received at least one preceding therapy or in first line use in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases.
Finally, American International Group, Inc. (NYSE:AIG), ended its last trade with 1.39% gain, and closed at $62.62.
American International Group, declared the closing of the sale of $1,250,000,000 aggregate principal amount of AIG’s 3.750% Notes due 2025, $500,000,000 aggregate principal amount of AIG’s 4.700% Notes due 2035 and $750,000,000 aggregate principal amount of AIG’s 4.800% Notes due 2045. AIG has determined that the closing of this notes offering satisfies the financing condition of its formerly declared maximum cash tender offer for certain notes and debentures issued or guaranteed by AIG described in the offer to purchase, dated June 18, 2015. The tender offer remains subject to certain other conditions, counting the absence of any adverse legal and market developments. The expiration date of the tender offer is 11:59 p.m., New York City time, on July 16, 2015, unless extended. The payment date for the tender offer will be promptly following its expiration and is predictable to be on or about July 20, 2015.
American International Group, Inc. provides insurance products and services for commercial, institutional, and individual customers in the United States, the Asia Pacific, and internationally. The company’s Commercial Insurance segment offers general liability, commercial automobile liability, workers’ compensation, excess casualty, and crisis administration causality insurance products; commercial, industrial, and energy-related property insurance products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
